Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Opthea (OPT) to raise $50 million for the development of OPT-302 as a therapy for wet Age-related Macular Degeneration (wet AMD)
  • The company will issue 18.9 million shares at $2.65 per share
  • Funds raised will go towards the development of OPT-302 for retinal eye diseases
  • Opthea is up 14.29 per cent on the market today and is selling shares for $3.12 apiece

Biopharmaceutical company Opthea, has received commitments to raise $50 million for the development of OPT-302 as a therapy for wet Age-related Macular Degeneration (wet AMD).

The company will issue 18.9 million shares at $2.65 per share to sophisticated and institutional investors in Australia and the United Kingdom.

“This institutional placement of $50 million at this time strengthens Opthea’s cash position as we explore a number of strategic development opportunities, and enables the company to fund its operations into the first half of the calendar year 2021,” CEO Megan Baldwin said.

Funds raised will go towards the development of OPT-302 for retinal eye diseases, such as wet AMD.

Wet AMD develops when abnormal blood vessels grow into the macula. These leak blood or fluid which leads to scarring of the macula and rapid loss of vision. Wet AMD can develop very quickly but it can be treated if caught early.

OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 molecule that blocks the activity of two proteins, VEGF-C and VEGF-D, that cause blood vessels to grow and leak.

“The completion of this placement will allow Opthea to expeditiously progress our Phase 3 clinical development program with OPT-302,” Megan said.

Opthea is up 14.29 per cent on the market today and is selling shares for $3.12 apiece at 1:57 pm AEDT.

OPT by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.